Status:
ACTIVE_NOT_RECRUITING
"Hepatic Substrate Flux Rates in Type 2 Diabetes"
Lead Sponsor:
German Diabetes Center
Collaborating Sponsors:
Yale University
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
NA
Brief Summary
Investigation of the effects of redox shuttle inhibition by metformin on gluconeogenic flux rates of lactate and glycerol in humans with type 2 diabetes
Detailed Description
Type 2 diabetes (T2D) is characterized by insulin resistance and relative insulin deficiency leading to hyperglycemia. Enhanced endogenous glucose production during fasting is a key feature of hepatic...
Eligibility Criteria
Inclusion
- Inclusion criteria:
- type 2 diabetes (duration \<7 years),
- age (18-75 years)
- BMI \<40 kg/m2
- HbA1c 6-15%
- Exclusion criteria:
- uncontrolled hyperglycaemia (\>340 mg/dl)
- diabetes types other than type 2 diabetes (ADA criteria)
- thiazolidinedione use during the preceding 6 months
- clinically relevant angiopathy, restrictive or obstructive lung diseases
- other acute or chronic diseases including wounds and the use of pharmacological agents known to affect insulin sensitivity, lipid metabolism or immunological function.
Exclusion
Key Trial Info
Start Date :
September 11 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 31 2025
Estimated Enrollment :
23 Patients enrolled
Trial Details
Trial ID
NCT04088851
Start Date
September 11 2019
End Date
December 31 2025
Last Update
January 13 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
German Diabetes Center
Düsseldorf, North Rhine-Westphalia, Germany, 40225